(DULUTH, Ga.) Boehringer Ingelheim announced today that investments of more than $80 million will be used to expand its existing facilities in St. Joseph, Mo. And Athens Ga. to accommodate increased production of animal vaccines.
The St. Joseph facility will begin to expand during the fourth quarter of 2017 adding on an additional 13,000-square-foot expansion to accommodate an increase in production of livestock animal vaccines sold in the U.S. and globally.
Currently, St. Joseph's operation is part of a 700,000-square-foot campus which includes a warehouse, research and development and other support functions.
The expansion is planned to be completed in the second half of 2019 and is expected to create 20 additional jobs over the next few years.
"The vaccines manufactured today in Athens and St. Joseph make a major difference for both the pets and livestock animals of our customers. The company has pioneered many important advancements in vaccines, and we continue to focus on health and prevention as core principles of our Animal Health business," Veronique Kodjo, global head of industrial operations for Boehringer Ingelheim's Animal Health business said. "These significant investments in expansion and capacity ensure that we can continue to support our future business growth areas."
The St. Joseph facility is the company's largest animal health manufacturing operation in the world and the site recently celebrated its 100th anniversary of being in the community.